News

Eye Hemorrhage Signals Myeloid Leukemia

Clinicians observe, diagnose, and treat a patient who displayed symptoms of one of the “most striking findings” in leukemia.


 

A 40-year-old man suddenly began to lose vision in his left eye. The retinal exam was normal for the right eye. But the left showed isolated subinternal limited membrane hemorrhage at the fovea along with a white-centered hemorrhage above the fovea.

The patient had no history of trauma or Valsalva retinopathy. His blood pressure was normal as was his blood glucose. However, when bloodwork showed a high total count, increased platelet count, and the peripheral smear indicated myeloid hyperplasia, clinicians at LV Prasad Eye Institute in Hyderabad, India, diagnosed the patient with underlying chronic myeloid leukemia (CML).

A physical examination revealed a palpable spleenomegaly—underscoring the fact, the clinicians note, that when an ophthalmologic finding suggests a systemic disease, a general physical examination will reveal more clinical clues. The patient was referred to an oncologist and started on imatinib for CML.

White-centered or pale-centered hemorrhages are believed to represent an accumulation of leukemic cells or platelet fibrin aggregates, the clinicians say. Blood dyscrasias, such as anemias, leukemia, multiple myeloma, and other platelet disorders may present with similar features. Such hemorrhages are known to resolve spontaneously when the patient is treated for the underlying condition, and the hematologic status improves, the clinicians say. This patient’s hemorrhage gradually resolved over the next month, and his visual acuity improved to 20/20.

Ocular manifestations as a presenting sign of leukemia, especially chronic, are rare, the clinicians say. They note that retinal hemorrhages are one of the “most striking findings” in leukemia, and because they can be directly observed, they provide a “subtle but important clue toward an otherwise asymptomatic disease.” If diagnosed early and treated promptly, patients with CML have a good survival rate.

Source:

Tyagi M, Agarwal K, Paulose RM, Rani PK. BMJ Case Rep. 2017;2017: pii: bcr-2017-21974.

doi: 10.1136/bcr-2017-219741.

Recommended Reading

Less lenalidomide may be more in frail elderly multiple myeloma patients
Federal Practitioner
Which Acute Myeloid Leukemia Patients are Good Immunotherapy Candidates?
Federal Practitioner
The Challenges of Precision Medicine and New Advances in Molecular Diagnostic Testing in Hematolymphoid Malignancies: Impact on the VHA (FULL)
Federal Practitioner
FDA approves first gene therapy – tisagenlecleucel for ALL
Federal Practitioner
FDA Approves New Leukemia Treatments
Federal Practitioner
Characterization of Hematology Consults for Complete Blood Count Abnormalities: A Single Center Experience in the Era of Electronic Consultation
Federal Practitioner
Evaluation of Fitness, Metabolism, and Quality of Life During Hematopoietic Stem Cell Transplant
Federal Practitioner
Do Post-Transplant Tests Show Recurring Multiple Myeloma?
Federal Practitioner
FDA Approves Treatment for Chronic GVHD
Federal Practitioner
Rare type of MCL mimics Castleman disease
Federal Practitioner